JAZZ Jazz Pharmaceuticals plc - Ordinary Shares
NASDAQ · Pharmaceuticals · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 3, 2026
$235,67
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$128,8052 haftanın en düşüğü
$266,3852 haftanın en yükseği
Piyasa Değeri (MRQ)
$15.27B
P/E (TTM)
16.1
Hisse Başına Kâr (TTM)
$14.63
Gelir (TTM)
$4.60B
rozetleriniz
52 Haftlık Aralık
$129–$266
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$294
P/E
16.1
ROE
22.1%
Net Kâr Marjı
20.4%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
JAZZ Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$235.67
Piyasa Değeri (MRQ)
$15.27B
P/E (TTM)
16.1
Hisse Başına Kâr (TTM)
$14.63
Gelir (TTM)
$4.60B
ROE (TTM)
22.1%
D/E Borç/Özsermaye (MRQ)
0.9
52 Haftlık Aralık
$129–$266
JAZZ Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Jazz Pharmaceuticals plc - Ordinary Shares Hakkında Wikipedia'dan şirket genel bakışı
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Company history and acquisitions
2010–2019
On 18 February 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia. In the following December, a new patent was issued for Sodium Oxybate.
On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat in Dublin became the headquarters of the combined company. Azur Pharma had been marketing specialty pharmaceutical products in the central nervous system (CNS) and women's health areas with US operations in Philadelphia.
On 26 April 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments). In September, the company sold its Women's Health business to Meda for $95 million. In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia.
In January 2014, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.
In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its then largest acquisition, with the purchase of Celator Pharmaceuticals for $1.5 billion. As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.
In August 2019, the company announced it would acquire Cavion Inc. for up to $310 million.
2020–present
In January 2021, Jazz announced it would acquire cannabis-focused medicinal drug company GW Pharmaceuticals for US$7.2 billion. This acquisition added the medication Epidiolex (cannabidiol), developed to treat severe epilepsy syndromes, to the company's portfolio.
In November 2025, Jazz Pharmaceuticals announced positive results from its Phase 3 trial for its cancer drug, Ziihera, a potential treatment for advanced gastroesophageal cancer.
Acquisition history
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriPharmaceuticals
çalışanlar2.890
ülkeIE
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$4.27B2016-12-31 → 2025-12-31
Hisse Başına Kâr$-5.842016-12-31 → 2025-12-31
Net kar marjı20.4%
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | JAZZ | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 16.15Y ort. ≈-12.5 | ≈-12.5 | · | · | |
| F/S (TTM) | 3.3 | · | · | · | |
| F/D (MRQ) | 3.2 | · | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | 9.6 | · | · | · | |
| Fiyat / Nakit Akışı (TTM) | 9.2 | · | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | 19.8 | · | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | JAZZ | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 19.5% | · | · | · | |
| Vergi Öncesi Kar Marjı (TTM) | 15.8% | · | · | · | |
| Net Kâr Marjı (TTM) | 20.4% | · | · | · | |
| ROA (TTM) | 8.5% | · | · | · | |
| ROE (TTM) | 22.1% | · | · | · |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | JAZZ | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.9 | · | · | · | |
| Cari Oran (MRQ) | 1.8 | · | · | · | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 0.7 | · | · | · |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | JAZZ | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 4.9%5Y ort. ≈13.0% | ≈13.0% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 5.3%5Y ort. ≈10.8% | ≈10.8% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 12.5% | · | · | · | |
| EPS YoY (EPS YB) | 41.8% | · | · | · | |
| Net Income YoY (Net Gelir Yıllık Bazda) | 35.0% | · | · | · | |
| EPS CAGR 3Y (EPS Bileşik Yıllık Büyüme Oranı 3Y) | 13.1% | · | · | · | |
| Net Income CAGR 3Y (Net Gelir Bileşik Yıllık Büyüme Oranı 3Y) | 20.2% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | JAZZ | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue / Employee (Çalışan Başına Gelir) | ≈$1.5M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-1.6%
Sonraki Rapor
Kas 03, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 3, 2026 | $5.71 | $6.30 | -9.4% |
| 31 Mart 2026 | $6.34 | $4.66 | 36.1% | |
| 31 Aralık 2025 | $6.64 | $6.65 | -0.11% | |
| 30 Eylül 2025 | $8.13 | $6.04 | 34.7% | |
| 30 Haziran 2025 | $-8.25 | $-7.76 | -6.4% | |
| 31 Mart 2025 | $1.68 | $4.75 | -64.6% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| R&D Expense | · | · | · | · | · | · | $300M | $227M | $198M | $162M | $135M | $85M | |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854M | $737M | $684M | $544M | $503M | $449M | $406M | |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896M | $817M | $977M | |
| Operating Income | $-430M | $717M | $579M | $-66M | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | |
| Interest Income | $86M | $106M | $65M | $12M | $2M | $11M | $20M | $17M | $4M | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $9M | |
| Pretax Income | $-628M | $470M | $298M | $-373M | $-113M | $275M | $454M | $529M | $441M | $532M | $436M | $152M | |
| Income Tax | $-272M | $-91M | $-120M | $-159M | $216M | $34M | $-73M | $80M | $-48M | $135M | $106M | $94M | |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | |
| Shares (Basic) | 60,981,000 | 61,838,000 | 63,291,000 | 62,539,000 | 59,694,000 | 55,712,000 | 56,749,000 | 59,976,000 | 60,018,000 | 60,500,000 | 61,232,000 | 59,746,000 | |
| Shares (Diluted) | 60,981,000 | 66,007,000 | 72,066,000 | 62,539,000 | 59,694,000 | 56,517,000 | 57,550,000 | 61,221,000 | 61,317,000 | 61,870,000 | 63,036,000 | 62,614,000 |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881M | $591M | $1.06B | $637M | $310M | $386M | $366M | $989M | $684M | |
| Receivables | $831M | $717M | $706M | $651M | $563M | $396M | $356M | $264M | $224M | $234M | $210M | $186M | |
| Inventory | $417M | $480M | $597M | $714M | $1.07B | $95M | $79M | $53M | $43M | $34M | $19M | $30M | |
| Prepaid Expense | $152M | $177M | $185M | $92M | $131M | $62M | $39M | $25M | $23M | $25M | $21M | $13M | |
| Other Current Assets | $324M | $262M | $321M | $267M | $252M | $152M | $79M | $68M | $77M | $29M | $19M | $21M | |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968M | $748M | $1.26B | $1.02B | |
| PP&E (Net) | · | · | · | · | · | $128M | $132M | $200M | $170M | $107M | $86M | $58M | |
| PP&E (Gross) | · | · | · | · | · | $196M | $187M | $250M | $211M | $140M | $109M | $74M | |
| Accum. Depreciation | · | · | · | · | · | $68M | $55M | $50M | $41M | $32M | $24M | $15M | |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958M | $920M | $928M | $948M | $894M | $657M | $703M | |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B | $1.19B | $1.44B | |
| Other Non-current Assets | $99M | $114M | $67M | $55M | $41M | $26M | $48M | $43M | $16M | $14M | $9M | $16M | |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Accounts Payable | $122M | $78M | $103M | $91M | $100M | $27M | $46M | $41M | $24M | $22M | $22M | $25M | |
| Accrued Liabilities | $1.03B | $911M | $794M | $803M | $666M | $353M | $270M | $265M | $199M | $193M | $164M | $164M | |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933M | $809M | $654M | $364M | $345M | $294M | $257M | $227M | $217M | |
| Capital Leases | $51M | $39M | $59M | $72M | $87M | $140M | $151M | $0 | · | · | · | · | |
| Deferred Tax | $594M | $677M | $848M | $944M | $1.30B | $130M | $224M | $309M | $383M | $557M | $283M | $375M | |
| Other Non-current Liabilities | $124M | $87M | $105M | $107M | $117M | $101M | $109M | $219M | $177M | $113M | $69M | $38M | |
| Long-term Debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B | $1.61B | $1.60B | $1.58B | $2.03B | $1.19B | $1.34B | |
| Common Stock | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $646M | $1.13B | $879M | $734M | $830M | $1.16B | $1.07B | $841M | $918M | $529M | $303M | $35M | |
| AOCI | $-569M | $-948M | $-842M | $-1.13B | $-400M | $-134M | $-223M | $-198M | $-141M | $-317M | $-267M | $-122M | |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B | $1.71B | $1.37B | |
| Liabilities + Equity | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Shares Outstanding | 61,400,000 | 60,600,000 | 62,255,000 | 63,214,000 | 61,633,000 | 56,171,000 | 56,140,000 | 57,704,000 | 58,898,000 | 59,820,000 | 61,305,000 | 60,643,000 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $42M | $33M | $30M | $30M | $27M | $19M | $15M | $15M | $13M | $12M | $10M | · | |
| Stock-based Comp | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | |
| Deferred Tax | $-445M | $-208M | $-260M | $-292M | $69M | $-137M | $-237M | $-89M | $-226M | $-41M | $-68M | $-49M | |
| Amort. of Intangibles | $655M | $627M | $608M | $599M | $526M | $260M | $355M | $201M | $152M | $102M | $98M | $127M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | |
| CapEx | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $10M | $36M | $36M | |
| Investing Cash Flow | $-1.51B | $-508M | $-163M | $-446M | $-5.21B | $-1.01B | $-155M | $-394M | $-269M | $-1.75B | $-2M | $-1.07B | |
| Stock Repurchased | $125M | $311M | $270M | $54.0K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | |
| Financing Cash Flow | $-873M | $21M | $-305M | $-529M | $3.97B | $528M | $-294M | $-479M | $-409M | $541M | $-214M | $711M | |
| Net Change in Cash | $-1.02B | $907M | $625M | $290M | $-466M | $420M | $328M | $-76M | $20M | $-623M | $305M | $48M | |
| Taxes Paid | $122M | $115M | $178M | · | · | · | · | · | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS (TTM) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.3% | 9.6% | 17.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | 41.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | · | 13.1% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | 35.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | · | 20.2% | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| Net Income TTM | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| P/E | -29.1 | 14.2 | 20.2 | -44.5 | -23.1 | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 | 26.9 | 176.1 | |
| P / Tangible Book | · | · | · | · | · | 18.3 | · | · | · | · | · | · | |
| Earnings Yield | -3.4% | 7.0% | 5.0% | -2.2% | -4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% | 3.7% | 0.57% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $898M | $1.09B | $1.05B | $1.02B | $902M | $1.01B | $972M | $957M | $893M | $972M | $941M | |
| SG&A Expense | $389M | $353M | $406M | $531M | $358M | $514M | $369M | $326M | $339M | $352M | $396M | $308M | $341M | $298M | $383M | $358M | |
| Operating Expenses | $960M | $732M | $943M | $1.07B | $1.73B | $954M | $897M | $795M | $824M | $836M | $889M | $800M | $800M | $767M | $1.24B | $916M | |
| Operating Income | $248M | $337M | $255M | $58M | $-686M | $-56M | $191M | $260M | $199M | $66M | $122M | $172M | $158M | $126M | $-263M | $25M | |
| Interest Income | $25M | $23M | $20M | $19M | $19M | $28M | $32M | $26M | $25M | $23M | $21M | $19M | $15M | $11M | $7M | $4M | |
| Pretax Income | $211M | $299M | $208M | $9M | $-736M | $-110M | $133M | $201M | $138M | $-2M | $62M | $100M | $82M | $55M | $-340M | $-60M | |
| Income Tax | $18M | $6M | $5M | $-242M | $-17M | $-18M | $-58M | $-15M | $-31M | $12M | $-33M | $-47M | $-24M | $-15M | $-100M | $-43M | |
| Net Income | $193M | $293M | $203M | $251M | $-718M | $-92M | $191M | $215M | $169M | $-15M | $94M | $147M | $104M | $69M | $-241M | $-20M | |
| EPS (Basic) | $3.05 | $4.73 | $3.28 | $4.14 | $-11.74 | $-1.52 | $3.11 | $3.50 | $2.68 | $-0.23 | $1.50 | $2.33 | $1.63 | $1.09 | $-3.86 | $-0.31 | |
| EPS (Diluted) | $2.78 | $4.43 | $3.34 | $4.08 | $-11.74 | $-1.52 | $2.97 | $3.42 | $2.49 | $-0.23 | $1.40 | $2.14 | $1.52 | $1.04 | $-3.85 | $-0.31 | |
| Shares (Basic) | 63,200,000 | 61,900,000 | · | 60,696,000 | 61,200,000 | 61,000,000 | · | 61,414,000 | 62,882,000 | 62,537,000 | · | 63,114,000 | 63,991,000 | 63,494,000 | · | 62,785,000 | |
| Shares (Diluted) | 69,400,000 | 66,100,000 | · | 61,606,000 | 61,200,000 | 61,000,000 | · | 63,174,000 | 69,625,000 | 62,537,000 | · | 71,293,000 | 73,540,000 | 73,771,000 | · | 62,785,000 | |
| EBITDA | $248M | $337M | · | $58M | $-686M | $-56M | · | $260M | $199M | $66M | · | $172M | $158M | $126M | · | $25M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | · | $1.34B | $1.28B | $1.17B | · | $839M | |
| Receivables | $881M | $836M | $831M | $764M | $714M | $653M | $717M | $724M | $698M | $707M | · | $628M | $610M | $624M | · | $601M | |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M | $543M | $577M | · | $612M | $657M | $675M | · | $728M | |
| Prepaid Expense | $200M | $150M | $152M | $147M | $164M | $150M | $177M | $155M | $134M | $123M | · | $110M | $107M | $73M | · | $93M | |
| Other Current Assets | $244M | $285M | $324M | $315M | $298M | $260M | $262M | $354M | $326M | $315M | · | $310M | $272M | $245M | · | $250M | |
| Current Assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | · | $3.25B | $3.01B | $2.78B | · | $2.57B | |
| Goodwill | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B | $1.80B | $1.74B | $1.74B | · | $1.71B | $1.74B | $1.72B | · | $1.59B | |
| Intangibles | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B | $5.14B | $5.08B | $5.24B | · | $5.42B | $5.71B | $5.76B | · | $5.57B | |
| Other Non-current Assets | $86M | $95M | $99M | $103M | $121M | $117M | $114M | $75M | $71M | $71M | · | $76M | $66M | $64M | · | $35M | |
| Total Assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Accounts Payable | $128M | $100M | $122M | $152M | $89M | $96M | $78M | $85M | $97M | $81M | · | $110M | $98M | $125M | · | $102M | |
| Accrued Liabilities | $1.03B | $1.02B | $1.03B | $1.00B | $875M | $1.06B | $911M | $859M | $801M | $827M | · | $770M | $748M | $712M | · | $668M | |
| Current Liabilities | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | · | $1.57B | $945M | $909M | · | $813M | |
| Capital Leases | $44M | $47M | $51M | $53M | $55M | $39M | $39M | $71M | $68M | $56M | · | $62M | $66M | $72M | · | $73M | |
| Deferred Tax | $529M | $548M | $594M | $629M | $682M | $671M | $677M | $792M | $775M | $810M | · | $841M | $911M | $932M | · | $934M | |
| Other Non-current Liabilities | $141M | $162M | $125M | $109M | $94M | $91M | $87M | $111M | $99M | $97M | · | $127M | $127M | $109M | · | $124M | |
| Long-term Debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Total Debt | $4.35B | $5.35B | · | $5.36B | $5.36B | $5.37B | · | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Common Stock | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $1.13B | $939M | $646M | $443M | $191M | $1.03B | $1.13B | $936M | $871M | $864M | · | $884M | $812M | $803M | · | $974M | |
| AOCI | $-662M | $-651M | $-569M | $-570M | $-486M | $-786M | $-948M | $-603M | $-888M | $-882M | · | $-1.04B | $-867M | $-980M | · | $-1.62B | |
| Stockholders' Equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B | $3.49B | $3.53B | $3.34B | $3.09B | $2.75B | |
| Liabilities + Equity | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Shares Outstanding | 64,800,000 | 62,700,000 | 61,435,000 | 60,740,000 | 60,640,000 | 61,623,000 | 60,631,000 | 60,443,000 | 61,745,000 | 63,028,000 | 62,255,000 | 62,945,000 | · | · | 63,214,000 | · |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $73M | $74M | $71M | $88M | $65M | $68M | $70M | $60M | $57M | $61M | $53M | $56M | $61M | $56M | $62M | $57M | |
| Deferred Tax | $-39M | $-66M | $-63M | $-271M | $-66M | $-44M | $-2M | $-64M | $-75M | $-66M | $-36M | $-79M | $-79M | $-66M | $-145M | $-65M | |
| Amort. of Intangibles | $170M | $172M | $170M | $168M | $162M | $154M | $159M | $157M | $155M | $156M | $152M | $155M | $152M | $150M | $137M | $141M | |
| Operating Cash Flow | $416M | $408M | $363M | $475M | $89M | $430M | $399M | $399M | $331M | $267M | $167M | $307M | $297M | $321M | $342M | $418M | |
| CapEx | $18M | $20M | $17M | $15M | $13M | $14M | $13M | $11M | $7M | $7M | $10M | $4M | $6M | $4M | $9M | $-5M | |
| Investing Cash Flow | $355M | $123M | $-372M | $-328M | $-641M | $-169M | $-193M | $214M | $-257M | $-272M | $102M | $-174M | $-86M | $-5M | $-324M | $5M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $150M | · | · | $100M | $74M | · | · | $0 | $0 | |
| Financing Cash Flow | $-994M | $-78M | $75M | $-11M | $-125M | $-814M | $-8M | $246M | $-161M | $-57M | $-100M | $-78M | $-97M | $-30M | $20M | $-289M | |
| Net Change in Cash | $-224M | $452M | $66M | $136M | $-672M | $-551M | $195M | $862M | $-88M | $-63M | $171M | $53M | $114M | $286M | $42M | $128M | |
| Free Cash Flow | · | $388M | · | · | · | $416M | · | · | · | $260M | · | · | · | $317M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| Net Margin | 16.0% | 27.4% | · | 22.3% | -68.7% | -10.3% | · | 20.4% | 16.5% | -1.6% | · | 15.1% | 10.9% | 7.8% | · | -2.1% | |
| Pretax Margin | 17.5% | 28.0% | · | 0.80% | -70.3% | -12.2% | · | 19.0% | 13.5% | -0.18% | · | 10.2% | 8.5% | 6.2% | · | -6.4% | |
| EBITDA Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| ROA | 1.8% | 2.5% | · | 2.1% | -6.4% | -0.81% | · | 1.8% | 1.5% | -0.13% | · | 1.4% | 0.93% | 0.61% | · | -0.17% | |
| ROE | 4.5% | 6.7% | · | 6.2% | -19.2% | -2.4% | · | 5.6% | 4.6% | -0.42% | · | 4.7% | 3.1% | 2.0% | · | -0.59% | |
| ROIC | 2.5% | 3.3% | · | 17.2% | -7.4% | -0.49% | · | 2.7% | 2.6% | 5.8% | · | 2.8% | 2.2% | 1.8% | · | 0.08% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 2.0 | · | 1.7 | 1.6 | 3.4 | · | 4.3 | 2.4 | 2.3 | · | 2.1 | 3.2 | 3.1 | · | 3.2 | |
| Quick Ratio | 1.1 | 1.2 | · | 0.9 | 0.9 | 2.1 | · | 2.9 | 1.3 | 1.4 | · | 1.2 | 2.0 | 2.0 | · | 1.8 | |
| Debt / Equity | 0.9 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.5 | · | 1.6 | 1.6 | 1.7 | · | 2.1 | |
| LT Debt / Equity | 0.7 | 1.0 | · | 1.1 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 2.1 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.5 | 1.4 | · | 1.5 | 1.5 | 1.3 | · | 1.6 | 1.6 | 1.4 | · | 1.6 | 1.6 | 1.5 | · | 1.7 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $74.10 | $72.29 | · | $65.18 | $61.12 | $67.75 | · | $69.01 | $60.94 | $58.65 | · | $55.44 | · | · | · | · | |
| Revenue / Share | $17.41 | $16.17 | · | $18.28 | $17.09 | $14.72 | · | $16.70 | $14.70 | $14.42 | · | $13.64 | $13.02 | $12.10 | · | $14.98 | |
| Cash Flow / Share | · | $6.18 | · | · | · | $7.05 | · | · | · | $4.27 | · | · | · | $4.35 | · | · | |
| Cash / Share | $25.00 | $29.41 | · | $21.83 | $19.62 | $30.22 | · | $36.70 | $21.96 | $22.90 | · | $21.22 | · | · | · | · | |
| EPS (TTM) | $14.63 | $0.11 | · | $-6.21 | $-6.87 | $7.36 | · | $7.08 | $5.80 | $4.83 | · | $0.85 | $-1.60 | $-2.57 | · | $-0.37 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.60B | $4.44B | · | $4.16B | $4.09B | $4.06B | · | $3.99B | $3.91B | $3.84B | · | $3.79B | $3.76B | $3.74B | · | $3.58B | |
| Net Income TTM | $941M | $29M | · | $-368M | $-405M | $482M | · | $463M | $395M | $331M | · | $80M | $-87M | $-156M | · | $-19M | |
| Market Cap | $15.61B | $11.85B | · | $8.01B | $6.44B | $7.65B | · | $6.73B | $6.59B | $7.59B | · | $8.15B | · | · | · | · | |
| Enterprise Value | $18.35B | $15.36B | · | $12.04B | $10.61B | $11.16B | · | $10.63B | $10.94B | $11.86B | · | $12.53B | · | · | · | · | |
| P/E | 16.5 | 1718.6 | · | -21.2 | -15.4 | 16.9 | · | 15.7 | 18.4 | 24.9 | · | 152.3 | -77.5 | -56.9 | · | -360.2 | |
| P/S | 3.4 | 2.7 | · | 1.9 | 1.6 | 1.9 | · | 1.7 | 1.7 | 2.0 | · | 2.1 | · | · | · | · | |
| P/B | 3.3 | 2.6 | · | 2.0 | 1.7 | 1.8 | · | 1.6 | 1.8 | 2.1 | · | 2.3 | · | · | · | · | |
| P / Cash Flow | · | 29.0 | · | · | · | 17.8 | · | · | · | 28.4 | · | · | · | · | · | · | |
| EV / Revenue | 4.0 | 3.5 | · | 2.9 | 2.6 | 2.7 | · | 2.7 | 2.8 | 3.1 | · | 3.3 | · | · | · | · | |
| Earnings Yield | 6.1% | 0.06% | · | -4.7% | -6.5% | 5.9% | · | 6.3% | 5.4% | 4.0% | · | 0.66% | -1.3% | -1.8% | · | -0.28% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Net Gelir | $-356M | $560M | $415M | $-224M | $-330M |
| Seyreltilmiş Hisse Başı Kâr | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
Bu beyan için veri yok
Bu beyanı oluşturmak için henüz yeterli temel verisi yok.
Bu beyan için veri yok
Bu beyanı oluşturmak için henüz yeterli temel verisi yok.
Kurumsal Sahipler (13F) 687 dosya · $15.8B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
687
Tutulan Değer
$15.8B
Yeni pozisyonlar
138
Çıkan pozisyonlar
56
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 138 (+32 önceki Ç'ye göre) | 56 (-21 önceki Ç'ye göre) | 240 (+24 önceki Ç'ye göre) | 188 (+19 önceki Ç'ye göre) | +942K |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $1.438.254.453 | 5.968.603 | 9,11% | Hisse senetleri |
| FMR LLC | $1.110.709.035 | 4.609.326 | 7,04% | Hisse senetleri |
| VANGUARD GROUP INC | $1.005.914.140 | 5.917.142 | 6,37% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $731.636.247 | 3.036.213 | 4,64% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $657.763.761 | 2.729.650 | 4,17% | Hisse senetleri |
| Capital World Investors | $650.043.082 | 2.697.610 | 4,12% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $491.639.148 | 2.040.250 | 3,12% | Hisse senetleri |
| STATE STREET CORP | $481.895.662 | 1.999.816 | 3,05% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $412.909.300 | 1.713.592 | 2,62% | Hisse senetleri |
| FULLER & THALER ASSET MANAGEMENT, INC. | $394.839.917 | 1.638.544 | 2,50% | Hisse senetleri |
| Bank of New York Mellon Corp | $380.253.849 | 1.578.013 | 2,41% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $359.935.093 | 1.522.568 | 2,28% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $357.440.125 | 1.483.031 | 2,26% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $292.895.571 | 1.215.523 | 1,86% | Hisse senetleri |
| JPMORGAN CHASE & CO | $276.634.191 | 1.160.786 | 1,75% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $273.763.940 | 1.136.091 | 1,73% | Hisse senetleri |
| CITADEL ADVISORS LLC | $242.578.716 | 1.006.676 | 1,54% | Hisse senetleri |
| Swedbank AB | $233.281.128 | 968.092 | 1,48% | Hisse senetleri |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $192.606.598 | 799.297 | 1,22% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $184.072.164 | 763.880 | 1,17% | Hisse senetleri |
| UBS Group AG | $182.381.760 | 756.865 | 1,16% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $165.478.678 | 686.719 | 1,05% | Hisse senetleri |
| NORGES BANK | $158.279.458 | 656.843 | 1,00% | Hisse senetleri |
| MORGAN STANLEY | $151.734.512 | 629.680 | 0,96% | Hisse senetleri |
| Mariner, LLC | $146.630.968 | 608.615 | 0,93% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $135.442.731 | 562.073 | 0,86% | Hisse senetleri |
| Allianz Asset Management GmbH | $131.345.759 | 545.071 | 0,83% | Hisse senetleri |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $129.891.746 | 539.037 | 0,82% | Hisse senetleri |
| NORTHERN TRUST CORP | $123.222.660 | 511.361 | 0,78% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $111.450.794 | 462.509 | 0,71% | Hisse senetleri |
| GMT Capital Corp | $109.279.895 | 453.500 | 0,69% | Hisse senetleri |
| Boston Trust Walden Corp | $106.779.349 | 443.123 | 0,68% | Hisse senetleri |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $105.278.106 | 436.893 | 0,67% | Hisse senetleri |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $103.893.734 | 431.148 | 0,66% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $96.439.086 | 400.212 | 0,61% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $95.008.929 | 394.277 | 0,60% | Hisse senetleri |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $91.259.201 | 378.715 | 0,58% | Hisse senetleri |
| Nuveen, LLC | $88.051.524 | 365.405 | 0,56% | Hisse senetleri |
| Sofinnova Investments, Inc. | $88.036.221 | 365.341 | 0,56% | Hisse senetleri |
| Polaris Capital Management, LLC | $79.270.937 | 328.966 | 0,50% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $77.695.234 | 322.427 | 0,49% | Hisse senetleri |
| GOLDENTREE ASSET MANAGEMENT LP | $70.838.675 | 294.435 | 0,45% | Hisse senetleri |
| Qube Research & Technologies Ltd | $70.056.003 | 290.725 | 0,44% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $67.434.009 | 279.844 | 0,43% | Hisse senetleri |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $66.815.854 | 277.279 | 0,42% | Hisse senetleri |
| Quantinno Capital Management LP | $65.906.960 | 273.506 | 0,42% | Hisse senetleri |
| BANK OF MONTREAL /CAN/ | $58.329.921 | 242.063 | 0,37% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $55.096.752 | 228.645 | 0,35% | Hisse senetleri |
| Tri Locum Partners LP | $53.427.868 | 221.720 | 0,34% | Hisse senetleri |
| Invesco Ltd. | $50.427.310 | 209.268 | 0,32% | Hisse senetleri |
Aktivistler ve %5+ sahipler 6 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 başvurular | 20 Haziran 2014 | · | İlk başvuru | · | SEC |
| KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 başvurular | 12 Mart 2013 | · | İlk başvuru | · | SEC |
| Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 başvurular | 14 Mart 2012 | · | İlk başvuru | Sermaye yapısı | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 başvurular | 30 Eylül 2011 | · | İlk başvuru | · | SEC |
| Azur Pharma Limited | 28 Eylül 2011 | · | İlk başvuru | M&A / satış | SEC |
| Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC | 28 Nisan 2005 | · | İlk başvuru | M&A / satış | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 56 içeriden öğrenenler · 18 yöneticiler · 20 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Renee D Gala | President & CEO | 08 Eylül 2026 S | 143.394 | 0 | 1 | $-486.060 |
| Philip L Johnson | EVP & Chief Financial Officer | 30 Haziran 2026 F | 56.431 | 0 | 0 | $0 |
| Matthew P. Young | EVP & CFO | 06 Mart 2019 S | 36.200 | 0 | 0 | $0 |
| Daniel N Swisher JR | President and COO | 05 Mart 2023 F | 55.014 | 0 | 0 | $0 |
| Christopher J. Tovey | EVP, COO & Managing Director E | 05 Temmuz 2022 M | 14.663 | 0 | 0 | $0 |
| Russell J. Cox | EVP & COO | 11 Aralık 2017 M | 102.821 | 0 | 0 | $0 |
| Neena M Patil | EVP & Chief Legal Officer | 10 Eylül 2026 S | 47.671 | 0 | 14 | $-11.500.359 |
| Mary Elizabeth Henderson | SVP, Technical Operations | 08 Eylül 2026 F | 23.815 | 0 | 2 | $-1.418.523 |
| Robert Iannone | EVP, Global Head of R&D & CMO | 27 Ağustos 2026 M | 65.686 | 0 | 7 | $-20.411.738 |
| Samantha Pearce | EVP, Chief Commercial Officer | 05 Ağustos 2026 F | 47.131 | 0 | 1 | $-1.625.977 |
| Patricia Carr | SVP, Chief Accounting Officer | 09 Mart 2026 S | 6.512 | 0 | 7 | $-2.458.091 |
| Kim Sablich | EVP, GM of U.S. | 05 Haziran 2023 D | 28.478 | 0 | 0 | $0 |
| Finbar Larkin | SVP, Technical Operations | 06 Mart 2023 M | 21.779 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | EVP, US Commercial | 12 Mart 2020 S | 22.118 | 0 | 0 | $0 |
| Paul Treacy | SVP, Technical Operations | 12 Ağustos 2019 S | 16.418 | 0 | 0 | $0 |
| Iain Mcgill | SVP, Europe & Rest of World | 05 Mart 2019 F | 24.938 | 0 | 0 | $0 |
| Karen J Wilson | SVP, Finance & PAO | 05 Mart 2019 F | 18.385 | 0 | 0 | $0 |
| Suzanne Sawochka Hooper | EVP & General Counsel | 27 Şubat 2019 M | 39.738 | 0 | 0 | $0 |
| Bruce C Cozadd | Yönetim kurulu üyesi | 01 Eylül 2026 S | 351.875 | 0 | 19 | $-26.393.546 |
| Patrick Kennedy | Yönetim kurulu üyesi | 31 Ağustos 2026 F | 6.452 | 0 | 0 | $0 |
| Mark Douglas Smith | Yönetim kurulu üyesi | 31 Ağustos 2026 F | 9.579 | 0 | 1 | $-266.746 |
| Jennifer E. Cook | Yönetim kurulu üyesi | 31 Ağustos 2026 F | 10.736 | 0 | 0 | $0 |
| Laura Hamill | Yönetim kurulu üyesi | 31 Ağustos 2026 F | 6.832 | 0 | 0 | $0 |
| Heather Ann Mcsharry | Yönetim kurulu üyesi | 31 Ağustos 2026 F | 18.199 | 0 | 2 | $-1.089.119 |
| Rick E Winningham | Yönetim kurulu üyesi | 31 Ağustos 2026 F | 9.466 | 0 | 2 | $-1.656.873 |
| Patrick G. Enright | Yönetim kurulu üyesi | 31 Ağustos 2026 F | 21.278 | 0 | 0 | $0 |
| Ted W Love | Yönetim kurulu üyesi | 31 Ağustos 2026 F | 2.389 | 0 | 0 | $0 |
| Norbert G Riedel | Yönetim kurulu üyesi | 31 Ağustos 2026 F | 6.923 | 0 | 1 | $-655.680 |
| Seamus Mulligan | Yönetim kurulu üyesi | 05 Ağustos 2026 A | 1.184.633 | 0 | 0 | $0 |
| Anne Oriordan | Yönetim kurulu üyesi | 08 Ağustos 2025 F | 16.500 | 0 | 0 | $0 |
| Peter Gray | Yönetim kurulu üyesi | 14 Ağustos 2023 S | 16.068 | 0 | 0 | $0 |
| Catherine A. Sohn | Yönetim kurulu üyesi | 14 Ağustos 2023 S | 14.868 | 0 | 0 | $0 |
| Elmar Schnee | Yönetim kurulu üyesi | 05 Ağustos 2021 S | 8.270 | 0 | 0 | $0 |
| Paul L Berns | Yönetim kurulu üyesi | 05 Ağustos 2021 S | 8.290 | 0 | 0 | $0 |
| Bryan C Cressey | Yönetim kurulu üyesi | 09 Mart 2012 S | 27.631 | 0 | 0 | $0 |
| Zilkha M Nathaniel | Yönetim kurulu üyesi | 10 Mart 2011 A | · | 0 | 0 | $0 |
| Alexander E Albert | Yönetim kurulu üyesi | 15 Ağustos 2008 A | · | 0 | 0 | $0 |
| Patel Jaimin | Yönetim kurulu üyesi | 15 Ağustos 2007 A | · | 0 | 0 | $0 |
| Kenneth W O'Keefe | · | 02 Aralık 2025 F | 25.811 | 0 | 0 | $0 |
| Karen L. Smith | · | 05 Mart 2018 F | 28.474 | 0 | 0 | $0 |
| Jeffrey K Tobias | · | 05 Mart 2015 F | 38.484 | 0 | 0 | $0 |
| Fintan Keegan | · | 08 Temmuz 2014 M | 31.750 | 0 | 0 | $0 |
| Kathryn E Falberg | · | 05 Mart 2014 F | 133.387 | 0 | 0 | $0 |
| James C Momtazee | · | 13 Ağustos 2013 S | 17.315 | 0 | 0 | $0 |
| Carol A Gamble | · | 09 Mart 2012 S | 32.213 | 0 | 0 | $0 |
| Alan Sebulsky | · | 09 Mart 2012 S | 54.355 | 0 | 0 | $0 |
| Samuel D Colella | · | 11 Ocak 2012 M | 38.347 | 0 | 0 | $0 |
| Michael W Michelson | · | 11 Ocak 2012 M | 13.885 | 0 | 0 | $0 |
| Mark G. Eller | · | 13 Ağustos 2011 M | 4.151 | 0 | 0 | $0 |
| Michael A. Desjardin | · | 13 Ağustos 2011 M | 14.574 | 0 | 0 | $0 |
| Janne Lt Wissel | · | 31 Mayıs 2011 J | 48.544 | 0 | 0 | $0 |
| Joan Colligan | · | 30 Kasım 2010 J | 14.424 | 0 | 0 | $0 |
| Robert M Myers | · | 30 Kasım 2010 J | 156.898 | 0 | 0 | $0 |
| James B Tananbaum | · | 25 Ağustos 2010 A | 21.366 | 0 | 0 | $0 |
| Samuel R Saks | · | 21 Ocak 2009 A | 358.868 | 0 | 0 | $0 |
| Matthew K Fust | · | 28 Kasım 2008 J | 58.948 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 61 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IHE · iShares Trust | 3,45% | 232.236 SH | 11 Eylül 2026 | Günlük |
| PJP · Invesco Exchange-Traded Fund Trust | 2,92% | 68.707 SH | 02 Ekim 2026 | Günlük |
| XMMO · Invesco Exchange-Traded Fund Trust | 2,29% | 699.736 SH | 02 Ekim 2026 | Günlük |
| PILL · Direxion Shares ETF Trust | 1,25% | 1.023 NS | 31 Temmuz 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,01% | 4.592 SH | 02 Ekim 2026 | Günlük |
| RFG · Invesco Exchange-Traded Fund Trust | 0,96% | 13.808 SH | 02 Ekim 2026 | Günlük |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,79% | 61.910 SH | 19 Ağustos 2026 | Günlük |
| PDP · Invesco Exchange-Traded Fund Trust | 0,64% | 40.761 SH | 02 Ekim 2026 | Günlük |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,58% | 14.802 NS | 31 Temmuz 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,54% | 27.352 NS | 31 Temmuz 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,49% | 8.679 SH | 02 Ekim 2026 | Günlük |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,41% | 101.353 SH | 19 Ağustos 2026 | Günlük |
| MIDU · Direxion Shares ETF Trust | 0,34% | 921 NS | 31 Temmuz 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,32% | 11.363 SH | 19 Ağustos 2026 | Günlük |
| VBR · VANGUARD INDEX FUNDS | 0,31% | 867.777 SH | 19 Ağustos 2026 | Günlük |
| VFMF · VANGUARD WELLINGTON FUND | 0,28% | 8.083 SH | 19 Ağustos 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,28% | 168.574 NS | 31 Temmuz 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,24% | 19.561 SH | 19 Ağustos 2026 | Günlük |
| IYH · iShares Trust | 0,23% | 34.871 SH | 11 Eylül 2026 | Günlük |
| ESML · iShares Trust | 0,22% | 25.740 SH | 11 Eylül 2026 | Günlük |
| DFAT · Dimensional ETF Trust | 0,22% | 123.193 NS | 31 Temmuz 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,20% | 166.548 SH | 19 Ağustos 2026 | Günlük |
| SMMD · iShares Trust | 0,20% | 31.945 SH | 11 Eylül 2026 | Günlük |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,18% | 9.978 SH | 02 Ekim 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,17% | 719.903 SH | 19 Ağustos 2026 | Günlük |
| VB · VANGUARD INDEX FUNDS | 0,17% | 1.366.973 SH | 19 Ağustos 2026 | Günlük |
| IWS · iShares Trust | 0,14% | 88.598 SH | 11 Eylül 2026 | Günlük |
| WSML · iShares Trust | 0,13% | 3.647 SH | 11 Eylül 2026 | Günlük |
| IWR · iShares Trust | 0,11% | 244.305 SH | 11 Eylül 2026 | Günlük |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 3.144 SH | 02 Ekim 2026 | Günlük |
| XT · iShares Trust | 0,09% | 13.710 SH | 11 Eylül 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,08% | 147.012 NS | 31 Temmuz 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,08% | 45.748 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,05% | 7.084 NS | 31 Temmuz 2026 | N-PORT |
| IUSG · iShares Trust | 0,04% | 55.258 SH | 11 Eylül 2026 | Günlük |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,04% | 36.014 SH | 19 Ağustos 2026 | Günlük |
| IWD · iShares Trust | 0,04% | 133.301 SH | 11 Eylül 2026 | Günlük |
| DSI · iShares Trust | 0,04% | 8.411 SH | 11 Eylül 2026 | Günlük |
| PRF · Invesco Exchange-Traded Fund Trust | 0,04% | 15.040 SH | 02 Ekim 2026 | Günlük |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 1.371 SH | 02 Ekim 2026 | Günlük |
| DFAU · Dimensional ETF Trust | 0,03% | 13.729 NS | 31 Temmuz 2026 | N-PORT |
| DYNF · BlackRock ETF Trust | 0,02% | 39.438 SH | 11 Eylül 2026 | Günlük |
| DXUV · Dimensional ETF Trust | 0,02% | 467 NS | 31 Temmuz 2026 | N-PORT |
| IYY · iShares Trust | 0,02% | 2.648 SH | 11 Eylül 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,02% | 17.349 NS | 31 Temmuz 2026 | N-PORT |
| ITOT · iShares Trust | 0,02% | 81.293 SH | 11 Eylül 2026 | Günlük |
| IWB · iShares Trust | 0,02% | 41.012 SH | 11 Eylül 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 1.892.855 SH | 19 Ağustos 2026 | Günlük |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 9.995 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 5.021 SH | 19 Ağustos 2026 | Günlük |
| ESGV · VANGUARD WORLD FUND | 0,02% | 13.490 SH | 19 Ağustos 2026 | Günlük |
| IWV · iShares Trust | 0,02% | 16.075 SH | 10 Eylül 2026 | Günlük |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 49.429 SH | 19 Ağustos 2026 | Günlük |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,01% | 1.238 SH | 02 Ekim 2026 | Günlük |
| NEAR · iShares U.S. ETF Trust | 0,00% | 200.000 SH | 09 Eylül 2026 | Günlük |
| IJH · iShares Trust | · | 2.201.423 SH | 11 Eylül 2026 | Günlük |
| IJK · iShares Trust | · | 363.871 SH | 11 Eylül 2026 | Günlük |
| XJH · iShares Trust | · | 8.572 SH | 08 Eylül 2026 | Günlük |
| ISCB · iShares Trust | · | 2.820 SH | 11 Eylül 2026 | Günlük |
| ISCV · iShares Trust | · | 13.894 SH | 11 Eylül 2026 | Günlük |
| SMMV · iShares Trust | · | 4.635 SH | 19 Ağustos 2026 | Günlük |
JAZZ Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 26 analist
AL
Medyan hedef
$300.00
+27,3%
7 26,9%
Güçlü Al
17 65,4%
Al
2 7,7%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
22 analist · 2026-10-03Ortalama hedef $294.27 +24,9%
Şimdi
Mevcut fiyat $235.67
Düşük$225.00
Ortalama$294.27
Yüksek$337.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 3, 2026